STATE STREET CORP Acquires Additional Shares in Agios Pharmaceuticals Inc

NodeGuardian · 2026-03-05T02:04:07+00:00

State Street Corp acquired 845,433 shares of Agios Pharmaceuticals, raising its total to 3,108,145 shares. Despite this investment signaling confidence, Agios faces financial challenges and risks of underperformance, as indicated by its valuation metrics.

NodeGuardian

2026-03-05 02:04:07

Abstract generation in progress

STATE STREET CORP acquired an additional 845,433 shares of Agios Pharmaceuticals Inc at $27.22 per share, increasing its holding to 3,108,145 shares, or 5.30% of its portfolio. Agios Pharmaceuticals specializes in developing medicines for rare diseases, particularly in classical hematology. While the transaction shows confidence in Agios, the company faces financial challenges, with a “possible value trap” GF Valuation and a GF Score of 53/100 indicating poor future performance potential.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.